Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2017 May 8;7:1519. doi: 10.1038/s41598-017-01771-8

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2017

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

LM-PLP infection protects mice from EAE in a CD8-dependent antigen-specific manner. (A) B6 mice were infected with LM-PLP or LM-OVA on d-7 and immunized with PLP178-191/CFA on d0 and monitored for clinical disease. (B) B6 mice were infected with LM-PLP or LM-OVA, followed by induction of EAE with non-cognate antigen MOG35-55/CFA. Disease scores are shown. (C) CD8-KO mice were infected with either LM-PLP or LM-OVA on d-7, immunized with PLP178-191/CFA on d0 and monitored for clinical disease. (D) CD8 T cells harvested from LM-PLP or LM-OVA-infected B6 mice were stimulated in vitro with PLP178-191 and OVA257-264 respectively, and adoptively transferred into naïve recipients followed by subsequent immunization with PLP178-191/CFA and the monitoring of clinical disease. (E) Perf-KO mice were infected with LM-PLP or LM-OVA on d-7, immunized with PLP178-191/CFA on d0, and monitored for clinical disease. (F) IFN-γ-KO mice were infected with LM-PLP or LM-OVA on d-7, immunized with PLP178-191/CFA on d0, and monitored for clinical disease as depicted. (G) Inflammation and (H) Spheroid/axon dilation scores from H&E stained lumbar spinal cord sections from infected and immunized mice on d18 post-immunization. Data are representative of at least two independent experiments in each panel. *p < 0.05, **p < 0.01, ***p < 0.001 ****p < 0.0001.